ArticleFolia microbiologica2025
Bioactive phytochemicals from Angelica glauca Edgew: a step toward novel therapeutics for respiratory tract infections.
Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to their vast chemical diversity, natural products derived from medicinal plants, whether as standardized extracts or isolated compounds, hold significant promise for new drug discovery. This study focused on the application of various analytical techniques, including phytochemical screening, extraction, isolation, and characterization of bioactive constituents from Angelica glauca extracts. The antibacterial properties of these isolated compounds were evaluated using the disk diffusion method against respiratory pathogens such as Staphylococcus aureus (MTCC 1144), Streptococcus pneumoniae (MTCC 655), Streptococcus pyogenes (MTCC 442), Pseudomonas aeruginosa (MTCC 2474), and Klebsiella pneumoniae (MTCC 4030). Findings revealed that the methanolic extract of A. glauca contains three primary bioactive compounds: n-hexacosane, stigmasterol, and 6,7-dimethoxycoumarin. Additionally, the extract was rich in alkaloids, flavonoids, glycosides, steroids, saponins, and tannins. Among the isolated compounds, 6,7-dimethoxycoumarin demonstrated the strongest antibacterial activity against S. aureus (17.0 ± 0.97 mm), outperforming n-hexacosane and stigmasterol. These results highlight the therapeutic potential of these compounds in treating respiratory infections and suggest their suitability as candidates for developing new antimicrobial agents. Future research will aim to formulate novel drugs based on these promising bioactive molecules.
Indexed as
Identifiers
41082033What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.